Why is Revolution Medicines stock surging today?

Revolution Medicines stock surged nearly 7.0% in mid-day trading as investors continued to digest a blowout third-quarter earnings report released after the close on November 4, in which the company posted $197.6 million in net product revenue from RASONQUE (daraxonrasib) — its newly FDA-approved oral RAS inhibitor for metastatic pancreatic cancer — despite the drug being on the market for only about five weeks. Third-quarter revenue reached $197.6 million, far above the consensus estimate, with nearly all of it coming from RASONQUE during its first five weeks on the U.S. market, while the company’s per-share loss was narrower than analysts had expected. Management noted that the initial revenue was driven by a combination of new patient starts, a backlog of patients awaiting treatment, and transitions from expanded access programs.

The earnings beat triggered a broad wave of analyst upgrades and price target hikes. HC Wainwright raised its price target on Revolution Medicines from $280.00 to $350.00, reiterating a "buy" rating in a research note issued today, November 6. RBC Capital also increased its target to $321 from $260 with an Outperform rating, while TD Cowen raised its target to $270 and Guggenheim lifted its target to $298, both maintaining Buy ratings. The company also reaffirmed its full-year 2026 operating expense guidance of $2.1 billion to $2.2 billion and ended the quarter with a robust cash and marketable securities balance of approximately $3.7 billion, up significantly from around $2 billion at the end of 2025.

From a broader market perspective, the macro environment is constructive for growth-oriented names today. Payer coverage for RASONQUE has reached 90% of U.S. lives, underscoring the commercial infrastructure Revolution Medicines has built around its first approved product. The NASDAQ is up 1.6% and the S&P 500 is up 0.9%, providing a supportive backdrop that amplifies momentum in high-growth biotech names like RVMD.

The combination of a historic commercial launch, a significant earnings beat relative to consensus, and a chorus of bullish analyst revisions has created a powerful upward catalyst for RVMD today. Adding to the longer-term pipeline narrative, global enrollment in RASolve 301 — the Phase 3 trial evaluating daraxonrasib in a second setting — is winding down, with an anticipated initial readout in 2027, giving investors additional future milestones to look forward to.